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Abstract
Background: Bleeding during hepatic surgery is associated with prolonged hospitalization and
increased morbidity and mortality. The Veriset™ haemostatic patch is a topical haemostat comprised of
an absorbable backing made of oxidized cellulose and self-adhesive hydrogel components. It is designed
to achieve haemostasis quickly and adhere to tissues without fixation.
Methods: A prospective, randomized, multicentre, single-blinded study (n = 50) was performed to
compare the use of a Veriset™ haemostatic patch with a fibrin sealant patch (TachoSil®) (control) in the
management of diffuse bleeding after hepatic surgery. Patients were randomized following the confirma-
tion of diffuse bleeding requiring the use of a topical haemostat. Time to haemostasis was assessed at
preset intervals until haemostasis was achieved.
Results: Both groups were similar in comorbidities and procedural techniques. The median time to
haemostasis in the group using the Veriset™ haemostatic patch was 1.0 min compared with 3.0 min in
the control group (P < 0.001; 3-min minimum application time for the control patch). This result was
independent of bleeding severity and surface area. Both products had similar safety profiles and no
statistical differences were observed in the occurrence of adverse or device-related events.
Conclusions: Regardless of bleeding severity or surface area, the Veriset™ haemostatic patch achieved
haemostasis in this setting significantly faster than the control device in patients undergoing hepatic
resection. It was safe and easy to handle in open hepatic surgery.
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Introduction
With the benefits of technical progress, meticulous knowledge
of surgical anatomy of the liver, improvements in perioperative
care and enhanced diagnostic imaging, hepatic surgery has
evolved during the last decades to include the resection of large or
multiple tumours.1 However, the ability to effectively perform
these surgeries is limited by the vascular anatomy, remnant liver
volume and impaired function caused by chemotherapy or cir-
rhosis. At the resection margin, larger vessels and bile ducts are
either ligated or clips are applied. However, independently of the
resection technique, bleeding frequently occurs, often triggered by
impaired coagulation. There are considerable benefits to both
patients and health care systems when haemostasis is addressed
efficiently.2,3 The rapid and effective treatment of bleeding during
and after hepatic surgery reduces blood loss and helps to decrease
perioperative complications. It subsequently reduces the need for
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intra- or postoperative transfusion, with its associated substantial
complication rate.4,5 Furthermore, effective management of bleed-
ing may reduce operative time and duration of hospital stay.
Frequently, hepatic bleeding sites are treated intraoperatively
with sutures, bipolar cautery, argon beam coagulation or infrared
coagulation.2,6 In instances in which bleeding cannot be controlled
with these methods, various additional measures are available,
including fibrin glue, patches containing the coagulation factors
fibrinogen and thrombin, as well as gelatin matrices containing
human thrombin. However, current methods of achieving hae-
mostasis have certain limitations. As the liver parenchyma is
fragile, clips and sutures may not effectively stop bleeding andmay
even lead to laceration of the liver tissue with increased haemor-
rhage. Similarly, coagulation of the parenchyma with bipolar
cautery or infrared coagulationmay not always be effective. Liquid
fibrin sealants reduce bleeding; however, as they require the appli-
cation of additional compression, they may be removed uninten-
tionally with gauze. Thus, solid, formable haemostatic patches
that induce coagulation have found their way into hepatic surgery
and are being widely used.
The Veriset™ (Covidien Inc., Mansfield, MA, USA) haemo-
static patch is a topical haemostatic agent that is comprised of an
oxidized cellulose backing impregnated with buffer salts, trily-
sine and polyethylene glycol (PEG) derived from non-animal
sources. The patch is absorbed within approximately 4 weeks
after application7 and does not contain animal-sourced materi-
als. In a swine model of hepatic resection, the Veriset™ haemo-
static patch stopped bleedings faster than an established
absorbable haemostat.7,8
The TachoSil® patch (Nycomed AS, Zurich, Switzerland) was
selected as the control agent as it has similar characteristics to the
Veriset™ haemostatic patch. Both products are patch-like, come
ready to use and are absorbed in situ. The TachoSil® has been used
successfully in hepatic surgery.9 Unlike the Veriset™ haemostatic
patch, the TachoSil® is coated with human coagulation factors to
aid in the coagulation cascade and contains equine collagen.10
Furthermore, the absorption of the TachoSil® is substantially
longer, occurring within approximately 12 weeks following appli-
cation. According to the manufacturer, slight pressure should be
applied to the TachoSil® on the bleeding site for a minimum of
3 min in order to achieve effective haemostasis.
The objective of this study was to compare the safety and effi-
cacy of the Veriset™ haemostatic patch with a fibrin sealant patch
as an adjunct to conventional haemostatic techniques during
hepatic surgery.
Materials and methods
Trial design
This study was a prospective, non-inferiority, multicentre, two-
arm, randomized, patient-blinded study to compare a haemo-
static patch (Veriset™) with a fibrinogen- and thrombin-coated
collagen patch (TachoSil®; control) in the management of bleed-
ing during hepatic surgery.
A 1 : 1 treatment randomization scheme, stratified by study
centre and the presence of cirrhosis, was generated prior to the
initiation of the study. Sealed envelopes were prepared for each
stratum and each study centre and were opened in a sequential
manner.
Although the study was a non-inferiority study, the sample size
was determined for a one-sided test for superiority based on the
primary effectiveness endpoint (median time to haemostasis)
with a power of 80%, an alpha of 0.025, and the assumption that
the true median times to haemostasis were 2.0 min and 3.0 min
for the Veriset™ and control patches, respectively.
This study was sponsored by Covidien, Inc.
Participants
The study was conducted at six institutions in Europe: theMedical
University of Innsbruck, Innsbruck, Austria; Ghent University
Hospital, Ghent, Belgium; University Hospitals Leuven, Leuven,
Belgium; University Hospital Heidelberg, Heidelberg, Germany;
Rechts der Isar Hospital, Technical University of Munich,Munich,
Germany, and Medical School Hanover, Hanover, Germany.
Only patients scheduled for non-emergent, open hepatic
surgery were eligible for inclusion in the study. Patients were
screened for study entry criteria preoperatively (within 30 days of
the scheduled surgical procedure) and intraoperatively. Patients
included in the study were aged18 years and had a target bleed-
ing site of generalized minor or moderate bleeding that persisted
on the cut surface of the liver, in which haemostasis was not
achieved utilizing conventional methods and which necessitated
the use of a topical haemostat. Patients were excluded from the
trial if they were undergoing a laparoscopic procedure that would
require the study treatment to be applied through a trocar, were
scheduled for a subsequent surgical procedure at the target bleed-
ing site, had a documented history of cirrhosis, had severe coagu-
lopathy [defined as an international normalized ratio (INR) of
>2.0], had a total bilirubin level of2.5 mg/dl, had an active local
infection at the target bleeding site, were pregnant, had a life
expectancy of <3 months, had received a liver transplant, or had
been treated with an investigational drug or device within 30 days
of enrolment. In addition, patients could be excluded if any inci-
dental preoperative finding was deemed by the investigator to
have potentially jeopardized the safety or welfare of the patient.
Interventions
Each investigator performed the surgical procedure according to
the appropriate standard procedures and practices at his institu-
tion. Primary haemostasis of the major vessels was achieved with
conventional methods (e.g. clips, cautery and sutures). The use of
argon beam coagulation was not allowed. If the patient had an
appropriate target bleeding site, he or she was randomized to
either the study treatment (Veriset™ haemostatic patch) or the
control (TachoSil®) group.
The Veriset™ haemostatic patch consists of two functional
components. The absorbable backing material is comprised of
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cellulose fibres woven into a high-strength three-dimensional
fabric that is oxidized. The hydrogel components include a multi-
arm reactive PEG, a low molecular weight amine and buffer salts.
The reactive components are kept physically distinct and dry until
they come into contact with physiological fluids.
Each treatment was applied in accordance with its respective
instructions for use. Upon application of the study treatment to
the target bleeding site, a stopwatch was started. In the control
group, according to the manufacturer’s instructions, the product
was left in situ for 3 min, at which point the first inspection was
made; this was followed by inspections every 30 s until bleeding
stopped. In the Veriset™ haemostatic patch group, the bleeding
site was inspected every 30 s from application of the patch until
bleeding stopped. If haemostasis was not achieved within
10 min, the investigator was allowed to use additional topical
haemostatic measures, excluding the haemostatic patch. Once
haemostasis was achieved, the procedure was considered
complete.
Outcome measures
The primary effectiveness endpoint was time to haemostasis.
Haemostasis achieved within 3 min was collected as a secondary
endpoint. Following application of the Veriset™ patch, the sur-
gical site was inspected at 30-s intervals for 5 min and then
at 1-min intervals for the next 5 min. In control subjects, the
initial assessments were made at 3 min after the application
of the patch, followed by assessments every 30 s for the next
2 min and then every minute for the next 5 min. For both
devices, once haemostasis was achieved, observation continued
for another minute to rule out re-bleeding. Differences in the
timing of the initial assessment reflect differences in the manu-
facturers’ recommended application procedures for the respec-
tive products.
Safety was assessed through the collection of treatment-
emergent adverse events (TEAEs) and postoperative bleeding
complications (bleeding that requires transfusion). Only events
occurring after randomization and during the 30-day follow-up
period were collected. The following postoperative events were
not captured as they were considered to be expected following a
surgical procedure performed under anaesthesia: procedure-
related transient nausea (within 4 days of the procedure);
procedure-related transient emesis (within 3 days of the proce-
dure); transient headache or pain responding to standard
medications; procedure- or medication-related constipation
responding to standard medications, and pain that the investiga-
tor considered common and expected (treated or untreated).
Other data captured included: vital signs; concomitant medi-
cations; clinical laboratory tests (including haematology, urea, cre-
atinine and liver function tests); rescue therapy (if applicable);
drainage output assessments (including time of placement/
removal, volume of drainage and clinically relevant findings);
length of hospital and/or intensive care unit (ICU) stay; transfu-
sion requirements, and evaluation of surgical site.
Statistical methods
Continuous variables were summarized using descriptive statis-
tics and categorical variables by frequencies and percentages. All
effectiveness analyses were performed using the intent-to-treat
population, which included all randomized patients. Safety
analyses were performed using the safety population and patients
were analysed according to the treatment they had actually
received.
The Kaplan–Meier method was used to estimate the distribu-
tion of time to haemostasis and to obtain the estimated median
time to haemostasis for each treatment. Patients who did not
achieve haemostasis within 10 min were censored at that time.
Brookmeyer–Crowley 95% confidence intervals (CIs) were com-
puted based upon the sign test.11 A non-inferiority comparison of
the treatments was performed using a one-sided log-rank test and
a non-inferiority margin of 1.0 with an alpha of 0.025. In addi-
tion, a superiority comparison was performed using a one-sided
log-rank test with an alpha of 0.025.
Numbers and percentages of patients who achieved haemosta-
sis within 3 min were compared between the two treatments using
the Suissa and Shuster test and the 95% CI for the true proportion
was computed for each treatment group.12 Post hoc effectiveness
analyses were conducted to address the imbalance between groups
at baseline in bleeding severity and area, and the difference and
discrepancy in the first observation period following application
of the device (30 s for the Veriset™ patch versus 3 min for the
TachoSil® control). The statistical tests used to perform the post
hoc analysis were the same as those used to assess the primary
efficacy measure (time to haemostasis).
Treatment-emergent adverse events were summarized by
MedDRA (Medical Dictionary for Regulatory Activities) system
organ class. Adverse events were categorized by severity (mild,
moderate or severe), seriousness (non-serious or serious), and
relationship to device (not related, possibly related, probably
related, definitely related, unknown/impossible to determine).
Comparisons between treatment groups for TEAEs and other
safety measures were made using Fisher’s exact test. All statistical
analyses were performed using sasVersion 9.1 (SAS Institute, Inc.,
Cary, NC, USA).
Results
Disposition
A total of 101 patients consented to their potential participation in
the study (Fig. 1). Of these, 50 met the intraoperative criteria and
were randomized to study treatment (32 to the Veriset™ group
and 18 to the TachoSil® control group). The most frequent reason
for not enrolling a consented patient was lack of an appropriate
target bleeding site (n = 45 patients, 88%). With the exception of
one patient, all patients received the treatment to which they had
been randomized.
In one patient, haemostasis was achieved using an argon beam
rather than with the control treatment as the investigator felt it
was in the best interests of the patient to do so. All but three
550 HPB
HPB 2013, 15, 548–558 © 2012 International Hepato-Pancreato-Biliary Association
patients completed the study. Two patients died during the study
(one in each treatment group), and one patient (in the control
group) requested to be withdrawn.
Demographic and baseline characteristics
No significant differences were observed between treatment
groups in any demographic or baseline characteristic. Patients
wereWhite, with a mean age of 62 years; 60%were male (Table 1).
One patient, in the Veriset™ patch group, had cirrhosis of the liver
(Child–Pugh class A). As expected in patients undergoing liver
resection, the majority had a past medical history of neoplasms.
The characteristics of the target bleeding sites are provided in
Table 2. Most patients had more than one source of bleeding;
venous bleeding was the most common source in both groups. A
greater percentage of patients in the control (56%) than in the
Veriset™ (41%) group had a moderate flow of blood, although
this difference did not reach statistical significance.
Procedural parameters
Table 3 provides data on the procedural parameters captured.
The most common types of resection performed were hemi-
hepatectomies and wedge resections. Multiple conventional
methods of haemostasis were used in each patient; cautery, clips
and sutures or ligatures were used most often. No significant
differences between treatment groups were noted in any of the
procedural parameters.
The size of the target bleeding site dictated the number of
devices applied; the majority of sites were treated with one or two
devices (94% and 77% of patients in the Veriset™ patch and
control groups, respectively). In all but four patients (two in each
treatment group), the initial treatment application was sufficient.
Of the patients who required an additional application, only one
(in the control group) did so as a result of bleeding through the
device. Other patients required additional applications because
the initial application did not fully cover the bleeding site.
The mean time required to perform the surgical procedure was
similar between the two groups (Veriset™ patch group, 252.5 
159.7 min; control group, 247.1  111.3 min; P = 0.899). Simi-
larly, no significant differences were observed in duration of ICU
stay (P = 0.67) or hospitalization (P = 0.301). Mean  standard
deviation (SD) durations of ICU stay and hospitalization were 2.8
 6.3 days and 15.2  9.2 days, respectively, in patients treated
with the Veriset™ patch, and 2.2 2.1 days and 18.5 12.0 days,
respectively, in patients in the control group.
Excluded*, n = 51
  Did not meet preoperative
       criteria n = 2
  No appropriate target bleeding site,
       n = 45
  Presence of intraoperative
       exclusion criteria, n = 16
  Other, n = 1
  Unknown, n = 4
Allocated, n = 18
Received intervention n = 17
Did not receive intervention n = 1
     Treated with non-study procedure
Completed follow-up, n = 31
Early discontinuation, n = 1
    Death, n = 1
Completed follow-up, n = 16
Early discontinuation, n = 2
     Death, n = 1
     Withdrawal by patient, n = 1
Analysed, n = 32 Analysed, n = 18
Allocated, n = 32
Received intervention n = 32
Enrolled
n = 101
Randomized
n = 50
Veriset™ haemostatic patch TachoSil
® (control)
Figure 1 CONSORT (consolidated standards of reporting trials) diagram of patient flow. *Patients may have failed more than one criterion
and thus percentages may sum to more than 100%
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Randomization
After 14 patients had been randomized, it was discovered that the
randomization was not a true permuted block randomization.
Consequently, a new randomization code was produced and used
to randomize subsequent patients (n = 36). Although not a true
permuted block randomization, the original randomization code
provided random assignment of patient to treatment and, for
completed blocks, produced the desired 1 : 1 allocation. Because
enrolment was a competitive process, not all blocks were
completed.
Effectiveness
The primary effectiveness endpoint was time to haemostasis.
Kaplan–Meier estimated distributions for time to haemostasis are
shown in Fig. 2. The Veriset™ haemostatic patch achieved hae-
mostasis significantly more quickly than the control device
(median time to haemostasis: 1.0 min versus 3.0 min; P < 0.001).
Post hoc analyses were performed to determine if differences in
bleeding severity and the size of the target bleeding site might
account for differences observed in the effectiveness of the two
treatments. As Table 4 shows, bleeding severity did not influence
time to haemostasis. For both minor and moderate bleeding,
median times to haemostasis were 1.0 min for the Veriset™ patch
and 3.0 min for the control device (P < 0.001). The same results
were observed for bleeding sites that were < 100 cm2 in size. For
bleeding sites that were 100 cm2, the Veriset™ patch also
achieved haemostasis more quickly than the control device
(median time to haemostasis: 1.0 min versus 4.0 min; P = 0.033).
In order to adjust for any potential bias caused by the difference
in the initial observation windows for the two products (within
30 s for the Veriset™ patch compared with 3 min for the control
device), a post hoc analysis was performed adjusting the time to
haemostasis of patients receiving the Veriset™ patch to a
minimum of 3 min. Following this adjustment, the difference
between treatments for time to haemostasis continued to be sig-
nificant (median time of 3.0 min in both groups; P < 0.001).
The percentage of patients achieving haemostasis within 3 min
was captured as a secondary effectiveness endpoint. Of the 32
Table 1 Demographic and baseline characteristics of the study population
Parameter Veriset™ group
(n = 32)
Control group
(n = 18)
P-value
Age, years, mean (SD) 62.2 (14.9) 62.0 (10.6) 0.957
Gender, male, n (%) 19 (59.4) 11 (61.1) 1.000
Race, White, n (%) 32 (100) 18 (100) –
Weight, kg, mean (SD) 72.43 (17.55) 75.45 (11.65) 0.518
Height, cm, mean (SD) 169.8 (9.2) 169.2 (7.7) 0.838
Concomitant diseases
Blood and lymphatic system disorders 1 (3.1) 0 1.000
Cardiac disorders 5 (15.6) 6 (33.3) 0.172
Endocrine disorders 5 (15.6) 4 (22.2) 0.705
Metabolism and nutrition disorders 11 (34.4) 6 (33.3) 1.000
SD, standard deviation.
Table 2 Characteristics of the target bleeding sites
Characteristic Veriset™ group
(n = 32)
Control group
(n = 18)
P-value
Source of bleed, n (%)a
Arterial 11 (34.4) 6 (33.3) 1.000
Venous 31 (96.9) 18 (100) 1.000
Capillary 17 (53.1) 8 (44.4) 0.769
Bleeding severity, n (%)b 0.382
Minor 19 (59.4) 8 (44.4)
Moderate 13 (40.6) 10 (55.6)
Approximate area, cm2, mean (SD) 69.0 (79.3) 89.0 (92.0) 0.423
aPercentages may sum to more than 100% as more than one category may apply to each patient.
bBleeding severity assessed at time of randomization.
SD, standard deviation.
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patients treated with the Veriset™ patch, 30 (94%, 95% CI 77.8–
98.9) achieved haemostasis within 3 min, compared with 12
(71%) of the 17 control group subjects (95% CI 46.0–88.0). This
indicates that 23% (95% CI 1.9–47.3) more patients achieved this
endpoint with the Veriset™ patch than with the control device
(P = 0.034). Furthermore, haemostasis was achieved within 4 min
in all patients who received the Veriset™ patch compared with 12
(71%) patients in the control arm.
Table 3 Procedural techniques
Parameter Veriset™ group
(n = 32)
n (%)
Control group
(n = 18)
n (%)
P-value
Resection typea
Hemi-hepatectomy
Left 5 (15.6) 1 (5.6) 0.399
Right 8 (25.0) 7 (38.9) 0.348
Bi-segmentectomy 6 (18.8) 3 (16.7) 1.000
Posterior section (right) 0 1 (5.6) 0.360
Tri-sectionectomy (right) 1 (3.1) 0 1.000
Wedge resection 13 (40.6) 7 (38.9) 1.000
Clamping technique
None 24 (75.0) 12 (66.7) 0.530
Pringle manoeuvre 6 (18.8) 6 (33.3) 0.310
Total vascular exclusion 1 (3.1) 0 1.000
Other 1 (3.1) 0 1.000
Conventional haemostatic procedures
Cautery 25 (78.1) 15 (83.3) 0.730
Clips 27 (84.4) 16 (88.9) 1.000
Staples 7 (21.9) 3 (16.7) 0.730
Suture/ligature 26 (81.3) 15 (83.3) 1.000
Other 0 1 (5.6) 0.360
aThe resection type in two patients was identified as ‘encapsulation’; these patients were not included in the analyses because encapsulation is not
identified within the Brisbane classification schema.
CUSA, Cavitron ultrasonic surgical aspirator; NT, not tested.
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Figure 2 Kaplan–Meier estimated distribution of time to haemolysis. Patients who had not achieved haemostasis within 10 min were
censored at that time
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Satisfaction
Following each surgical procedure, the surgeon rated his or her
satisfaction regarding ease of use and overall satisfaction with the
device using a 5-point Likert scale (1 = easy/satisfied, 5 = difficult/
not satisfied). In 88% (28/32) and 100% (16/16) of cases in the
Veriset™ haemostatic patch and control groups, respectively, the
surgeon gave an overall satisfaction rating of 1 or 2. Similarly, for
overall ease of use, surgeons gave a rating of 1 or 2 in 91% (29/32)
and 100% (16/16) of cases in the Veriset™ patch and control
groups, respectively.
Device malfunctions and rescue therapy
None of the patients required rescue therapy prior to determina-
tion of the primary endpoint. After the primary endpoint had
been determined, none of the patients treated with the control
device required rescue therapy; however, three patients treated
with the Veriset™ patch required rescue therapy. In two of these
patients, the device became detached from the bleeding site prior
to the completion of the surgical procedure. These events were
managed through cauterization or the use of a topical agent.
The third patient who required rescue therapy developed arte-
rial bleeding after achieving haemostasis, but prior to the closure
of the incision. In this instance, the bleeding emanated through
the haemostatic patch and was treated with additional sutures.
Postoperative follow-up
Drains were placed in all patients and the volume and clinically
significant findings (as assessed by the investigator) of drainage
were collected. Clinically significant findings were reported in five
(16%) patients in the Veriset™ patch group compared with one
(6%) in the control group. Among patients treated with the Veri-
set™ patch, instances of biloma (n = 2), haematoma (n = 1),
intra-abdominal abscess (n = 1) and inferior vena cava occlusion
withmulti-organ failure (n = 1) were reported. The patient treated
with the control device experienced re-bleeding.
Safety
A total of 131 TEAEs occurring in 76% (37/49) of patients were
reported. Of these, three were considered by the investigator to be
related to the device (Veriset™ patch group: one event each of
post-procedural bile leak and hematoma; control group: one
event of post-procedural haemorrhage). Serious TEAEs were
reported in 10 (31%) and eight (47%) patients in the Veriset™
patch and control groups, respectively. The majority of the TEAEs
were of mild or moderate intensity [mild in 36 (49%) patients in
the Veriset™ patch group and 29 (51%) patients in the control
group; moderate in 29 (39%) patients in theVeriset™ patch group
and 20 (35%) patients in the control group]. Ascites, pleural effu-
sion, abnormal hepatic function, pyrexia and wound dehiscence
were the most frequently reported TEAEs (Table 5). No significant
differences in the number (overall, serious, device-related), sever-
ity or type of TEAEs were observed between treatments.
Clinical laboratory values were similar in both groups. Table 6
provides coagulation and creatinine levels over the course of the
study. No significant differences between groups were noted in
Table 4 Post hoc analysis of time to haemostasis based on bleeding severity and area
Stratification variablea Median time to haemostasis, min P-value
Non-inferiority
P-value
Superiority
Veriset™ group
(n = 32)
Control group
(n = 18)
Bleeding severity
Minor 1.00 3.00 <0.001 <0.001
Moderate 1.00 3.00 <0.001 <0.001
Approximate area
<100 cm2 1.00 3.00 <0.001 <0.001
100 cm2 1.00 4.00 0.014 0.033
aBleeding severity assessed at the time of randomization.
Note: Three patients were excluded from the analysis because of potential data entry errors (i.e. values outside the normal range).
Table 5 Treatment emergent adverse events occurring in two or
more patients in either treatment arm: safety population
Preferred term Veriset™
group
(n = 32)
n (%)
Control
group
(n = 17)
n (%)
Any treatment emergent adverse events 23 (71.9) 14 (82.4)
Ascites 5 (15.6) 2 (11.8)
Hepatic dysfunction (PoD 30) 4 (12.5) 1 (5.9)
Hepatic enzymes increased (PoD 30) 0 2 (11.8)
Pleural effusion 4 (12.5) 3 (17.6)
Biloma 3 (9.4) 0
Pyrexia 3 (9.4) 2 (11.8)
Anaemia postoperative 2 (6.3) 0
Nausea/vomiting 3 (9.4) 4 (23.6)
Pneumonia 2 (6.3) 0
Pulmonary embolism 2 (6.3) 0
Localized intra-abdominal fluid collection 0 2 (11.8)
Wound complications 3 (9.4) 9 (52.9)
PoD, postoperative day.
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changes from baseline values for INR, prothrombin time (PT) or
partial thromboplastin time (PTT).Although creatinine remained
relatively consistent over the course of the study in the Veriset™
patch group, patients treated with the control device experienced
a significant decrease in creatinine. Consequently, the statistically
significant difference between groups in the change from baseline
can be attributed to the decrease within the control group.
Although the percentage of patients requiring a transfusion of
blood or plasma tended to be lower in the Veriset™ patch group,
the difference between the groups did not reach statistical signifi-
cance (Table 7). In addition, no significant differences between
groups were noted in the number or volume of transfusions
required.
Two deaths occurred during the trial, one in each of the treat-
ment arms. Both deaths were the result of multiple organ failure.
The treating surgeon and an independent medical monitor
(blinded to treatment assignment and site at which the patient was
enrolled) considered the deaths to be unrelated to the study device.
Concomitant medications
Almost all patients (94% in the Veriset™ patch arm and 100% in
the control arm) received antibiotics perioperatively. The use of
anti-thrombotic or anti-haemorrhagic agents during the course
of the study is summarized in Table 8. No anti-thrombotic or
anti-haemorrhagic agent was used intraoperatively. Use of
anti-thrombotics was relatively similar between groups. Anti-
haemorrhagics were used only postoperatively prior to discharge.
Discussion
Intraoperative bleeding during hepatic surgery is of clinical rel-
evance. As a consequence, blood units are needed, operative time
is extended and the risk for postoperative complications and
tumour recurrence is increased.4,5,13,14 Similarly, postoperative
haemorrhage causes morbidity by its requirements for interven-
tion and blood transfusions and the risk for infectious complica-
tions.15,16 Blood transfusion during liver resection for primary and
secondary malignancies has been identified as an independent
prognostic variable for tumour recurrence.5,13,17,18
As long as bleedings at the resection margin can be controlled
with conservative measures, as was the case in the 45 patients in
the present series who were not enrolled into the study, no further
measures are required. However, as a result of the oozing of small
vessels, haemostyptic agents or devices are frequently needed in
order to achieve haemostasis properly and in a timelymanner. The
Veriset™ haemostatic patch has been developed with the purpose
of offering surgeons a device that rapidly achieves local bleeding
control.
In this multicentre, controlled, randomized study, the Veriset™
haemostatic patch was compared with the TachoSil®, an estab-
lished device that is used frequently in liver resections.9 The aim of
this study was to evaluate the efficacy and safety of the Veriset™
haemostatic patch for regulatory approval. Not surprisingly, as
this effect had already been observed in animal models,8 the patch
achieved haemostasis more rapidly than the control device, inde-
pendent of bleeding severity, size of bleeding site or differences in
the observation window. The method to assess time to haemosta-
sis was limited by the manufacturer’s recommendation to allow
3 min for the control device to achieve efficacy under local com-
pression; this is not necessary with the Veriset™ patch. Thus, the
percentage of patients who achieved haemostasis after 3 min was
defined as a secondary endpoint to confirm the results. The ability
of the patch to achieve haemostasis is based on its excellent hae-
mostatic properties, as demonstrated in experimental studies.7,8,19
Table 6 Coagulation parameters
Parameter Veriset™ group
(n = 32)
Control group
(n = 18)
P-valuea
n Mean (SD) n Mean (SD)
International normalized ratio
Baseline 32 1.018 (0.075) 17 1.042 (0.092)
Postoperative 27 1.040 (0.081) 14 1.109 (0.122) 0.196
Day 30 follow-up 26 1.065 (0.144) 14 1.116 (0.111) 0.396
Prothrombin time, %
Baseline 29 99.91 (10.54) 15 96.80 (13.93)
Postoperative 25 96.52 (12.28) 13 88.15 (11.59) 0.183
Day 30 follow-up 24 94.94 (15.91) 13 86.67 (13.55) 0.226
Partial thromboplastin time, s
Baseline 32 37.53 (20.45) 17 43.19 (26.56)
Postoperative 27 38.80 (20.35) 14 35.88 (10.65) 0.482
Day 30 follow-up 24 42.69 (23.60) 15 42.85 (23.87) 0.059
aResult from a two-sample t-test testing the difference between treatments in mean change from baseline.
SD, standard deviation.
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The two primary components of the Veriset™ haemostatic
patch are oxidized cellulose and PEG. Oxidized cellulose is the
oldest haemostyptic agent known in surgery and was first
described in 1943.20 Furthermore, the antimicrobial properties of
oxidized cellulose may provide an additional clinical benefit.21–23
These properties, coupled with its ability to bind to other chemi-
cals, have resulted in the use of oxidized cellulose in a number of
haemostatic products. Polyethylene glycol provides the ability to
absorb fluids quickly. The inclusion of PEG provides a method of
sealing a wound quickly while maintaining its flexibility to expand
and contract. Because PEG is synthetic, it does not pose a risk for
viral transmission and is not dependent on the body’s natural
coagulation cascade.24
Reducing time to haemostasis has several implications: it
decreases the need for blood units (and consequently reduces the
risk for blood transfusion-related transmission of infectious
disease); it shortens operating times; it decreases hospital stay, and
it lowers the incidence of postoperative complications. All of these
impacts are primarily advantageous for the patient, but they also
result in reduced costs to the health care system.25,26 The numbers
of patients requiring blood or plasma transfusions or i.v. anti-
haemorrhagics were similar in both study arms, again demon-
strating the non-inferiority of the investigational device compared
with the control. Certainly, it would have been beneficial to quan-
tify blood loss in this study; however, total blood loss during the
operation may not accurately reflect reductions in blood loss
attributable to the device as blood loss may occur during the
entire procedure and not only in relation to uncontrollable bleed-
ing at target sites. Patients with life-threatening haemorrhages
were not included into this study according to the investigators’
decisions.
After completion of the observation period, haemostasis was
achieved in all patients treated with the Veriset™ haemostatic
patch; however, in three patients haemostasis was not definite
and additional measures were taken. In two patients, the patch
detached from the resection site as a result of the mobilization of
the liver after application of the patch. By contrast with the control
device, the Veriset™ haemostatic patch is more rigid and less
flexible and may be deemed disadvantageous in specific cases, but
in other cases may be advantageous. In addition, all participants in
this study were using the Veriset™ haemostatic patch for the first
time and this may have had an influence by its imposition of a
Table 7 Blood and plasma transfusions
Parameter Veriset™ group
(n = 32)
Control group
(n = 18)
P-value
Blood
Prior to randomization, n (%) 6 (18.8) 2 (11.1) 0.694
Number of transfusions, mean (SD) 1.0 (0.0) 1.0 (0.0) –
Volume, ml, mean (SD) 2316.7 (2494.3) 375.0 (176.8) 0.337
Day 0, after randomization 4 (12.5) 5 (27.8) 0.253
Number of transfusions, mean (SD) 1.0 (0.0) 1.0 (0.0) –
Volume, ml, mean (SD) 760.0 (597.8) 1180.0 (641.9) 0.349
After day 0 7 (21.9) 8 (44.4) 0.117
Number of transfusions, mean (SD) 1.3 (0.5) 2.0 (1.9) 0.337
Volume, ml, mean (SD) 744.3 (390.0) 1568.1 (2111.6) 0.312
Plasma
Prior to randomization, n (%) 3 (9.4) 4 (22.2) 0.235
Number of transfusions, mean (SD) 1.0 (0.0) 1.0 (0.0) –
Volume, ml, mean (SD) 2133.3 (1616.6) 1400.0 (400.0) 0.517
Day 0, after randomization 3 (9.4) 1 (5.6) 1.000
Number of transfusions, mean (SD) 1.0 (0.0) 1.0 (0.0) –
Volume, ml, mean (SD) 720.0 (520.0) 400.0 (0.0) –
After day 0 2 (6.3) 5 (27.8) 0.083
Number of transfusions, mean (SD) 2.0 (1.4) 2.0 (1.4) 1.000
Volume, ml, mean (SD) 2180.0 (1668.8) 2610.0 (2629.5) 0.843
Table 8 Use of anti-thrombotic and anti-haemorrhagic agents
Concomitant medication Veriset™
group
(n = 32)
Control
group
(n = 18)
Anti-thrombotic agents
Preoperative 12 (37.5) 7 (38.9)
Postoperative, prior to discharge 24 (75.0) 13 (72.2)
Postoperative, after discharge 4 (12.5) 3 (16.7)
Anti-haemorrhagic agents
Postoperative, prior to discharge 9 (28.1) 3 (16.7)
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learning curve. It may be assumed that these ‘malfunctions’ will
become less frequent as experience with the patch increases. Simi-
larly, the third patient in whom treatment of the bleeding site
failed may not have shown favourable indications for the use of
the Veriset™ haemostatic patch because the device was developed
for diffuse bleedings rather than for isolated severe arterial bleed-
ings (as documented in this patient), which often cannot be
stopped with any of the devices currently available other than
sutures. It should be noted that at 4 min, haemostasis was
achieved in 100% of patients treated with the Veriset™ haemo-
static patch compared with 71% of patients in the control arm.
No increase in TEAEs was observed in theVeriset™ haemostatic
patch group, underlining the non-inferiority of the patch. What
complications might the placement of a novel device on a target
bleeding site induce? Firstly, thematerial might cause local inflam-
mation or even infection; this was seen in a single patient (but not
necessarily as a consequence of the use of the patch), who finally
succumbed to multi-organ failure after multiple complications
unrelated to the use of the patch. Further, no systemic allergic
reactions were seen. However, the incidence of biloma was higher
in the Veriset™ group, although not significantly so and remained
within the range of incidence seen routinely after liver resection.27
Further studies will clarify this issue and establish whether, with
respect to sealing of the resection margin, the Veriset™ haemo-
static patch is as effective as other measures in avoiding bilomas.
Additionally, it is not known whether biliary leakage occurred at
the target bleeding site or at any other site of the resection margin
that was not covered by the patch. Other than the case noted
earlier, no local abscesses were observed and the fact that the
bilomas were not infected may be attributed to the antimicrobial
properties of oxidized cellulose, which have been demonstrated
experimentally.21 Two cases of pulmonary embolism occurred in
the Veriset™ patch group. Based on the pathogenesis of pulmo-
nary embolism, these are not believed to bear any direct associa-
tion to the patch, although awareness of this issue is important for
further studies. Similarly, the higher number of pulmonary infec-
tions is unlikely to be associated with use of the patch. Further,
there is no conclusive explanation for the higher number of
patients found to have liver dysfunction at postoperative day 30 in
the Veriset™ patch group.
Two properties of the Veriset™ haemostatic patch were not
specifically analysed in this study, but should be mentioned: the
patch is absorbed more quickly (within 4 weeks versus 12 weeks)
and this may reduce the risk for local infections. Further, the patch
does not contain any animal-sourced material and thus the trans-
mission of infectious disease is excluded.
Although this study did not capture economic measures asso-
ciated with the use of the Veriset™ haemostatic patch, the results
reported here may translate into cost savings. A recent study indi-
cated that patients with perioperative blood loss stay longer in
hospital and may have a higher mortality rate compared with
those who do not experience perioperative blood loss, and the use
of haemostyptics may impose a significant burden on hospital
resources.28 Further studies are required to elucidate whether lim-
iting the time required to reach haemostasis, as seen with the
Veriset™ haemostatic patch, can improve both clinical and
economic outcomes.
Finally, satisfaction with the Veriset™ haemostatic patch
amongst surgeons was comparable with the satisfaction attributed
to the use of the control product, underlining the simple use of the
Veriset™ patch, which can be easily applied to the target bleeding
site with no measures other than local pressure.
In summary, this controlled, multicentre, randomized study
comparing the novel non-animal-sourced Veriset™ haemostatic
patch with an established fibrin/thrombin-coated equine collagen
patch revealed the non-inferiority of the tested device and favour-
able outcomes concerning time to haemostasis. These findings
indicate that theVeriset™ haemostatic patch should be considered
for use during hepatic resections to manage bleeding sites that
cannot be controlled with conventional methods.
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